09:08 AM EDT, 09/09/2025 (MT Newswires) -- Teva Pharmaceutical (TEVA) said Tuesday that the US Food and Drug Administration has granted Fast Track designation to its investigational therapy emrusolmin for the treatment of patients with multiple system atrophy.

Emrusolmin is a small molecule that targets the alpha-synuclein protein, which is involved in the pathogenesis of multiple system atrophy, the company said, adding that emrusolmin is currently undergoing a mid-stage trial to assess its efficacy and safety.